Nytenso 10

Indications

Nytenso is prescribed for the management of Major Depressive Disorder (MDD) in adults, offering relief from depressive symptoms and improving overall mood.
Always consult a registered healthcare provider before use.

Pharmacology

Nytenso (Vortioxetine) enhances serotonergic activity in the brain by inhibiting serotonin reuptake. It also functions as a 5-HT3 receptor antagonist and 5-HT1A receptor agonist, contributing to its antidepressant effects. The exact mechanism remains partially understood, but it plays a role in alleviating depressive symptoms.

Dosage & Administration

• Starting Dose: 10 mg once daily. This may be increased to 20 mg/day, depending on tolerance.
• Elderly Patients (65+ years): Start with 5 mg/day.
• Maintenance: Can be taken long-term; regular evaluation of its effectiveness is advised.
• Discontinuation: Gradually reduce the dose to 10 mg/day for one week before discontinuation to minimize withdrawal effects.
• Switching from MAOIs: Allow at least 14 days between stopping an MAOI and starting Nytenso. Conversely, wait 21 days after discontinuing Nytenso before starting an MAOI.

Follow your healthcare provider’s instructions for correct administration.

Drug Interactions

• MAOIs: Serious reactions can occur if Nytenso is combined with MAOIs.
• Serotonergic Medications: Combining Nytenso with other serotonergic drugs (e.g., SSRIs, SNRIs, Triptans) can increase the risk of serotonin syndrome.
• Other CNS Drugs: Lithium exposure is unaffected by Nytenso, but dose adjustments may be needed when combined with certain CYP inhibitors or inducers.

Contraindications

Nytenso is contraindicated in patients with known hypersensitivity to Vortioxetine or any of its ingredients. It should not be combined with Monoamine Oxidase Inhibitors (MAOIs).

Side Effects

Common side effects may include hypersensitivity reactions, suicidal thoughts, serotonin syndrome, and abnormal bleeding. Rare but serious effects include angle-closure glaucoma and hyponatremia. Seek medical attention for any concerning symptoms.

Pregnancy & Lactation

• Pregnancy: Safety in pregnancy has not been established. Nytenso should only be used if the potential benefits outweigh the risks.
• Lactation: Vortioxetine is excreted into breast milk. It is not recommended during breastfeeding.

Precautions & Warnings

• Suicide Risk: Monitor closely for signs of worsening depression or suicidal thoughts, especially during the first few weeks of treatment.
• Serotonin Syndrome: Watch for signs like agitation, confusion, and rapid heartbeat, especially when combined with other serotonergic drugs.
• Bleeding Risk: Avoid co-administration with NSAIDs or blood thinners unless advised by a doctor.

Special Populations

• Pediatric Use: Not recommended for children under 18.
• Elderly: No dose adjustment necessary.
• Renal or Hepatic Impairment: No dose adjustment for mild or moderate renal or hepatic impairment. Avoid in severe cases.
• CYP2D6 Poor Metabolizers: Reduced metabolism may require a dose adjustment.

Overdose Effects

Symptoms may include nausea, dizziness, and drowsiness. Immediate medical attention is necessary if an overdose occurs.

Therapeutic Class

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Storage Conditions

Store Nytenso in a dry place at or below 30°C, away from direct light, and out of the reach of children.